MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, being developed for metabolic and alcohol-associated liver diseases. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Last trade$1.27
Day change+$0.06 (+4.98%)
Day range$1.19 – $1.37
Volume89,200
Market cap$8M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.16M
Price / earnings
—
Price / book
1.2×
Price / sales
—
EV / sales
—
EV / EBITDA
0.11×
Profitability
Earnings per share
-$2.14
Return on assets
-108.85%
Return on equity
-211.76%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.42×
Current ratio
2.06×
Quick ratio
2.06×
Cash ratio
1.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.84M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MTVA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.91M
$1.92M
$1.81M
$1.56M
$1.98M
$1.56M
$1.53M
Research and development
$3.48M
$2.1M
$241K
$1.91M
$2.32M
$2.33M
$4.06M
Total operating expenses
$5.39M
$4.03M
$2.05M
$3.48M
$4.3M
$3.89M
$5.59M
Operating income
-$5.39M
-$4.03M
-$2.05M
-$3.48M
-$4.3M
-$3.89M
-$5.59M
Interest expense
$73K
$0
$85K
$151K
$146K
$0
$209K
Income before taxes
-$5.32M
-$3.82M
-$1.93M
-$3.38M
-$4M
-$3.67M
-$5.17M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.32M
-$3.82M
-$1.93M
-$3.38M
-$4M
-$3.67M
-$5.17M
Net income attributable to common shareholders
-$5.32M
-$3.82M
-$1.93M
-$3.38M
-$4M
-$3.67M
-$5.17M
EBITDA
-$5.38M
-$4.02M
-$2.04M
-$3.47M
-$4.3M
-$3.88M
-$5.58M
Basic earnings per share
-$0.90
-$0.79
-$0.77
-$1.54
-$2.87
-$3.93
-$5.53
Diluted earnings per share
-$0.90
-$0.79
-$0.77
-$1.54
-$2.87
-$3.93
-$5.53
Recent news
Company coverage with links to the original publishers.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
The MASH (Metabolic Dysfunction-Associated Steatohepatitis) market is rapidly expanding with over 180 companies developing 200+ pipeline therapies. Two drugs have been approved: REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals and LIPAGLYN/BILYPSA (saroglitazar magnesium) by Zydus Lifesciences. The competitive landscape is intensifying with emerging mechanisms of action including FGF21 replacements, GLP-1 receptor agonists, and dual glucagon/GLP-1 agonists, with approximately 5+ drugs in late-stage development and 100+ in mid and early stages.
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.